Interv Akut Kardiol. 2021;20(1):28-32

Perspectives in the treatment of heart failure

Filip Málek
Kardiovaskulární centrum, Nemocnice Na Homolce, Praha

The future of the treatment of heart failure is based on methods aimed at slowing or reversing the progressive course of the disease. In patients in a less advanced stage of heart failure, the research is focused on the modulation of autonomic regulation and cardiac remodeling in HFrEF. New interventional methods are also tested in patients with HFpEF.

Keywords: heart failure, autonomic regulation, cardiac remodeling, interventional methods.

Received: October 20, 2020; Revised: November 24, 2020; Accepted: November 24, 2020; Prepublished online: November 24, 2020; Published: April 29, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Perspectives in the treatment of heart failure. Interv Akut Kardiol. 2021;20(1):28-32.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Roger VL. Epidemiology of Heart Failure Circ Res 2013; 113: 646-659. Go to original source... Go to PubMed...
    2. Udelson JE, Stevenson LW. The future of heart failure, diagnosis, therapy and management Circulation 2016; 133: 2671-2686. Go to original source... Go to PubMed...
    3. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal 2016; 37(27): 2129-2200. Go to original source... Go to PubMed...
    4. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association Circulation 2017; 135(10): e146-e603. Go to original source... Go to PubMed...
    5. Zipes DP, Neuzil P, Theres H, et al. For DEFEAT-HF Trial Investigators. Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study. JACC Heart Fail 2015; (6): S2213-1779.
    6. Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C, Klein H, et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. European Heart Journal 2014; 36 (7): 425-433. Go to original source... Go to PubMed...
    7. Abraham WT, Zile MR, Weaver FA, et al. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail 2015; (6): 487-496. Go to original source... Go to PubMed...
    8. Kahwash R, Burkhoff D, Abraham WT. Cardiac contractility modulation in patients with advanced heart failure. Expert Rev Cardiovasc Ther 2013; 11(5): 635-645. Go to original source... Go to PubMed...
    9. Bauters Ch, Dubois E, Porouchani S, et al. Long-term prognostic impact of left ventricular remodeling after a first myocardial infarction in modern clinical practice PloS ONE 2017; 11(12): e01888864 Go to original source...
    10. Klein P, Anker S, Wechsler A, et al. Less invasive ventricular reconstruction for ischemic heart failure Eur J Heart Fail 2019; 31: 1638-1650. Go to original source... Go to PubMed...
    11. An Early Feasibility Evaluation of the AccuCinch® Ventricular Repair System in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF) - The CorCinch-HFrEF Studyhttps://clinicaltrials.gov/ct2/show/NCT03533517.
    12. Søndergaard L, Reddy V, Kaye D, et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail 2014; 16: 796-801. Go to original source... Go to PubMed...
    13. Hasenfuss G, Hayward C, Burkhoff D, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): A multicentre, open-label, single-arm, phase 1 trial. The Lancet 2016; 387(10025): 1298-1304. Go to original source... Go to PubMed...
    14. Feldman T, Mauri L, Kahwash RM, et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]) A Phase 2, Randomized, Sham-Controlled Trial Circulation 2018; 137: 364-375. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.